The discovery of N-((2 H-tetrazol-5-yl)methyl)-4-((R)-1-((5 r,8 R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl) -4,4-dimethylpentyl)benzamide (SCH 900822): A potent and selective glucagon receptor antagonist

Journal of Medicinal Chemistry

Volumn 57, Issue 6, 2014, Pages 2601-2610

  Demong, Duane ^a   Dai, Xing ^a   Hwa, Joyce ^a   Miller, Michael ^a   Lin, Sue Ing ^a   Kang, Ling ^a   Stamford, Andrew ^a   Greenlee, William ^a   Yu, Wensheng ^a   Wong, Michael ^a   Lavey, Brian ^a   Kozlowski, Joseph ^a   Zhou, Guowei ^a   Yang, De Yi ^a   Patel, Bhuneshwari ^a   Soriano, Aileen ^a   Zhai, Ying ^a   Sondey, Christopher ^a   Zhang, Hongtao ^a   Lachowicz, Jean ^a   Grotz, Diane ^a   Cox, Kathleen ^a   Morrison, Richard ^a   Andreani, Teresa ^a   Cao, Yang ^a   Liang, Mark ^a   Meng, Tao ^a   McNamara, Paul ^a   Wong, Jesse ^a   Bradley, Prudence ^a   Feng, Kung I ^a   Belani, Jitendra ^b   Chen, Ping ^b   Dai, Peng ^b   Gauuan, Jolicia ^b   Lin, Peishan ^b   Zhao, He ^b   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b ALBANY MOLECULAR RESEARCH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCOSE; HORMONE RECEPTOR BLOCKING AGENT; N [(2H TETRAZOL 5 YL)METHYL] 4 [1 [8 (TERT BUTYL) 3 (3,5 DICHLOROPHENYL) 2 OXO 1,4 DIAZASPIRO[4.5]DEC 3 EN 1 YL] 4,4 DIMETHYLPENTYL]BENZAMIDE; SCH 900822; STREPTOZOCIN; UNCLASSIFIED DRUG; N-((2H-TETRAZOL-5-YL)METHYL)-4-(1-(8-(TERT-BUTYL)-3-(3,5-DICHLOROPHENYL)-2-OXO-1,4-DIAZASPIRO(4.5)DEC-3-EN-1-YL)-4,4-DIMETHYLPENTYL)BENZAMIDE; BENZAMIDE DERIVATIVE; CYCLOHEXANONE DERIVATIVE; GLUCAGON; N ((2H TETRAZOL 5 YL)METHYL) 4 (1 (8 (TERT BUTYL) 3 (3,5 DICHLOROPHENYL) 2 OXO 1,4 DIAZASPIRO(4.5)DEC 3 EN 1 YL) 4,4 DIMETHYLPENTYL)BENZAMIDE; SPIRO COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; LIPID DIET; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; EXPERIMENTAL DIABETES MELLITUS; IMPAIRED GLUCOSE TOLERANCE; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; BENZAMIDES; BLOOD GLUCOSE; CYCLOHEXANONES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DRUG DISCOVERY; GLUCAGON; MICE; MICE, INBRED ICR; OBESITY; PREDIABETIC STATE; RECEPTORS, GLUCAGON; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84897441737     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401858f     Document Type: Article

References (30)

1. IDF Diabetes Atlas, 6 th ed.; Guariguata, L., Nolan, T., Beagley, J., Linnenkamp, U., Jacqmain, O., Eds.; International Diabetes Federation: Brussels, Belgium.
2. Kimball, C. P.; Murlin, J. R. Aqueous Extracts of Pancreas: III. Some Precipitation Reactions of Insulin J. Biol. Chem. 1923, 58, 337-346
3. Bromer, W.; Winn, L.; Behrens, O. The Amino Acid Sequence of Glucagon. V. Location of Amide Groups, Acid Degradation Studies and Summary of Sequential Evidence J. Am. Chem. Soc. 1957, 79, 2807-2810
4. Ferner, H. The A- and B-Cells of the Pancreatic Islets as Sources of the Antagonistic Hormones Glucagon and Insulin. The Shift of the AB-Relation in Diabetes Mellitus Am. J. Dig. Dis. 1953, 20, 301-306
5. Jelinik, L. J.; Lok, S.; Rosenberg, G. B.; Smith, R. A.; Grant, F. J.; Biggs, S.; Bensch, P. A.; Kuijper, J. L.; Sheppard, P. O.; Sprecher, C. A.; O'Hara, P. J.; Foster, D.; Walker, K. M.; Chen, L. H. J.; McKernan, P. A.; Kindsvogel, W. Expression Cloning and Signaling Properties of the Rat Glucagon Receptor Science 1993, 259, 1614-1616
6. Mayo, K. E.; Miller, L. J.; Bataille, D.; Dalle, S.; Goke, B.; Thorens, B.; Drucker, D. J. International Union of Pharmacology. XXXV. The Glucagon Receptor Family Pharmacol. Rev. 2003, 55, 167-194
7. Pohl, S. L.; Birnbaumer, L.; Rodbell, M. Glucagon-Sensitive Adenyl Cylase in Plasma Membrane of Hepatic Parenchymal Cells Science 1969, 164, 566
8. Struck, E.; Ashmore, J.; Wieland, O. Stimulierung der Gluconeogenese durch langkettige Fettsäuren und Glucagon Biochem Z. 1965, 343, 107-110
9. Exton, J. H.; Park, C. R. D. The Stimulation of Gluconeogenesis from Lactate by Epinephrine, Glucagon and Cyclic 3′,5′-Adenylate in the Perfused Rat Liver Pharmacol. Rev. 1966, 18, 181
10. DeMong, D. E.; Miller, M. W. Glucagon Receptor Antagonists in Development. In RSC Drug Discovery Series, Issue 27; New Therapeutic Strategies for Type 2 Diabetes; Jones, R., Ed.; The Royal Society of Chemistry: Cambridge, UK, 2012; pp 429-463.
11. Shen, D.-M.; Lin, S.; Parmee, E. R. A Survey of Small Molecule Glucagon Receptor Antagonists from Recent Patents (2006-2010) Expert Opin. Ther. Pat. 2011, 21, 1211-1240
12. DeMong, D. E.; Miller, M. W.; Lachowicz, J. E. Glucagon Receptor Antagonists for Type II Diabetes. In Annual Report on Medicinal Chemistry; Macor, J. E., Ed.; Academic Press: London, UK, 2008; Vol. 43, pp 119-137.
13. Sloop, K. W.; Michael, M. D.; Moyers, J. S. Glucagon as a Target for the Treatment of Type 2 Diabetes Expert Opin. Ther. Pat.ents 2005, 9, 593-600
14. Ling, A. L.; Wasserman, J. I. Approaches to Glucagon Receptor Antagonists Expert Opin. Ther. Pat. 2003, 13, 15-22
15. Petersen, K. F.; Sullivan, J. T. Effects of a Novel Glucagon Receptor Antagonist (Bay 27-9955) On Glucagon-Stimulated Glucose Production in Humans Diabetologia 2001, 44, 2018-2024
16. Xiong, Y.; Guo, J.; Candelore, M. R.; Liang, R.; Miller, C.; Dallas-Yang, Q.; Jiang, G.; McCann, P. E.; Qureshi, S. A.; Tong, X.; Xu, S. S.; Shang, J.; Vincent, S. H.; Tota, L. M.; Wright, M. J.; Yang, X.; Zhang, B. B.; Tata, J. R.; Parmee, E. R. Discovery of a Novel Glucagon Receptor Antagonist N -[(4-{(1 S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1 H -pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes J. Med. Chem. 2012, 55, 6137-6148
17. Parmee, E. R. Discovery of MK-0893: A Glucagon Receptor Antagonist for the Treatment of Type II Diabetes. Abstracts of Papers, 241st ACS National Meeting & Exposition; Anaheim, CA, United States, March 27-31, 2011; MEDI-31.
18. Ruddy, M.; Pramanik, B.; Lunceford, J.; Li, S.; Cilissen, C.; Stoch, S. A.; Wagner, J.; Amatruda, J.; Herman, G.; Kaufman, K. Inhibition of Glucagon-Induced Hyperglycemia Predicts Glucose Lowering Efficacy of a Glucagon Receptor Antagonist, MK-0893, in Type 2 Diabetes (T2DM). Abstracts of 71st Scientific Sessions of the American Diabetes Association; June 24-28, 2011; Abstract number 0311-OR.
19. Engel, S. S.; Xu, L.; Andryuk, P. J.; Davies, M. J.; Amatruda, J.; Kaufman, K.; Goldstein, B. J. Efficacy and Tolerability of MK-0893, a Glucagon Receptor Antagonist (GRA), in Patients with Type 2 Diabetes (T2DM). Abstracts of 71st Scientific Sessions of the American Diabetes Association; June 24-28, 2011; Abstract number 0309-OR.
20. Tham, L. S.; Abu-Raddad, E. J.; Lim, C. N.; Loh, M. T.; Ng, W. T.; Pinaire, J. A.; Kelley, R. P. The Glucagon Receptor Antagonist LY2409021 Attenuates Increases in Hepatic Glucose Output (HGO) and Blood Glucose during Hyperglucagonemia in Healthy Male Subjects. Abstracts of 71st Scientific Sessions of the American Diabetes Association; June 24-28, 2011; Abstract number 0416PP.
21. Kelley, R. P.; Garhyan, P.; Abu-Raddad, E. J.; Fu, H.; Lim, C. N.; Prince, M. J.; Pinaire, J. A.; Loh, M. T.; Deeg, M. A. Short-Term Treatment with Glucagon Receptor Antagonist LY2409021 Effectively Reduces Fasting Blood Glucose (FBG) and HbA1c in Patients with Type 2 Diabetes Mellitus (T2DM). Abstracts of 71st Scientific Sessions of the American Diabetes Association, June 24-28, 2011; Abstract number 0305OR.
22. Lau, J.; Behrens, C.; Sidelmann, U. G.; Knudsen, L. B.; Lundt, B.; Sams, C.; Ynddal, L.; Brand, C. L.; Pridal, L.; Ling, A.; Kiel, D.; Plewe, M.; Shi, S.; Madsen, P. New β-Alanine Derivatives Are Orally Available Glucagon Receptor Antagonists J. Med. Chem. 2007, 50, 113-128
23. Kodra, J. T.; Steen Jorgensen, A.; Andersen, B.; Behrens, C.; Lehn Brand, C.; Thoeger Christensen, I.; Gulbrandt, M.; Bekker Jeppesen, C.; Knudsen, L. B.; Madsen, P.; Nishimura, E.; Sams, C.; Sidelmann, U. G.; Pedersen, R. A.; Lynn, F. C.; Lau, J. Novel Glucagon Receptor Antagonists with Improved Selectivity over the Glucose-Dependent Insulinotropic Polypeptide Receptor J. Med. Chem. 2008, 51, 5387-5396
24. Shen, D.-M.; Zhang, F.; Brady, E. J.; Candelore, M. R.; Dallas-Yang, Q.; Ding, V. D.-H.; Dragovic, J.; Feeney, W. P.; Jiang, G.; McCann, P. E.; Mock, S.; Qureshi, S. A.; Saperstein, R.; Shen, X.; Tamvakopoulos, C.; Tong, X.; Tota, L. M.; Wright, M. J.; Yang, X.; Zheng, S.; Chapman, K. T.; Zhang, B. B.; Tata, J. R.; Parmee, E. R. Discovery of Novel, Potent, And Orally Active Spiro-Urea Human Glucagon Receptor Antagonists Bioorg. Med. Chem. Lett. 2005, 15, 4564-4569
25. Pernet-Poil-Chevrier, A.; Cantagrel, F.; Le Jeune, K.; Philouze, C.; Chavant, P. Y. New Chiral Nitrones as Precursors of α,α- Disubstituted Amino-Acids, According to the SRS Principle Tetrahedron: Asymmetry 2006, 17, 1969-1974
26. Cheng, S.; Wu, H.; Hu, X. Versatile Spirocyclic Glycine-Based Nitrones and Their Highly Stereoselective 1,3-Dipolar Cycloaddition Synth. Commun. 2007, 37, 297-308
27. Aouadi, K.; Jeanneau, E.; Msaddek, M.; Praly, J.-P. Analogues of Insulin Secretagogue (2 S,3 R,4 S)-4-Hydroxyisoleucine: Synthesis by 1,3-Dipolar Cycloaddition Reactions of Chiral Nitrones to Alkenes Tetrahedron: Asymmetry 2008, 19, 1145-1152
28. DeMong, D. E.; Ng, I.; Miller, M. W.; Stamford, A. W. A Novel Method for the Preparation of 4-Arylimidazolones Org. Lett. 2013, 15, 2830-2833
29. Cogan, D. A.; Liu, G.; Ellman, J. Asymmetric Synthesis of Chiral Amines by Highly Diastereoselective 1,2-Additions of Organometallic Reagents to N-tert -Butanesulfinyl Imines Tetrahedron 1999, 55, 8883-8904
30. 3 as an Activating and Dehydrating Reagent Synlett 2004, 457-460